Program
Naproxen
Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.
Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.
Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 240 open or running | phase 4since Apr 15, 2010 | Jun 5, 2008 | none ahead |
| Pfizerits history only | 80 open or running | phase 4since Mar 28, 2008 | Aug 17, 2006 | none ahead |
| GlaxoSmithKline | 70 open or running | phase 4since Nov 17, 2008 | Oct 14, 2005 | none ahead |
| Aralez Pharmaceuticalsits history only | 60 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Merckits history only | 40 open or running | phase 4since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 20 open or running | phase 3since Jul 7, 2011 | Jul 7, 2011 | none ahead |
| Perrigoits history only | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Analgesic Solutionsits history only | 10 open or running | no phasesince Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Kenvue Brandsits history only | 11 open or running | phase 3since Oct 15, 2026 | Oct 15, 2026 | Oct 29, 2027phase 3 · NCT07948811 |
Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2005First study: phase 3 study in Migraine DisordersFirst studyNCT00240617 · 623 enrolled · United States
- May 22, 20062 phase 3 studies in Migraine DisordersNCT00329459, NCT00329355
- Oct 11, 2006Phase 3 study in Migraine without AuraNCT00387881 · 679 enrolled · United States
- Nov 17, 2008Phase 4 study in Migraine DisordersNCT00792636 · 407 enrolled · United States
- Feb 12, 2009Phase 3 study in Migraine DisordersNCT00843024 · 589 enrolled · United States
- Oct 28, 2010Phase 2 study in OsteoarthritisNCT01231490 · 53 enrolled · United Kingdom
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 137 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 7 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01231490Osteoarthritis · United Kingdom | 2 | Completed | Jan 2009 | 53 |
| NCT00843024Migraine Disorders · United States | 3 | Completed | May 2010 | 589 |
| NCT00792636Migraine Disorders · United States | 4 | Completed | Nov 2009 | 407 |
| NCT00387881Migraine without Aura · United States | 3 | Completed | Feb 2008 | 679 |
| NCT00329459Migraine Disorders · United States | 3 | Completed | Nov 2006 | 320 |
| NCT00329355Migraine Disorders · United States | 3 | Completed | Nov 2006 | 351 |
| NCT00240617Migraine Disorders · United States | 3 | Completed | Jun 2006 | 623 |
How it is read
Names in the registry
- “Naproxen”, 17 entries
- “PN400”, 8 entries
- “naproxen”, 5 entries
- “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
- “Naproxen Sodium ER (BAYH6689)”, 4 entries
Conditions, from the studies’ own filings
- Pain, 12 studies
- Osteoarthritis, 9 studies
- Migraine Disorders, 8 studies
- Osteoarthritis, Knee, 5 studies
- Pain, Postoperative, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.